S 160202

Drug Profile

S 160202

Alternative Names: NSC 659687; NSC D 659687; Olivacine derivative; S 16020

Latest Information Update: 26 Oct 2006

Price : $50

At a glance

  • Originator Servier
  • Class Antineoplastics
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 26 Oct 2006 Discontinued - Phase-II for Solid tumours in France (IV-infusion)
  • 29 Dec 2000 Phase-II clinical trials in Solid tumours in France (IV-infusion)
  • 22 Mar 2000 A phase I study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top